Surgery Partners - SGRY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.75
  • Forecasted Upside: 49.83 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$29.20
▲ +0.64 (2.24%)

This chart shows the closing price for SGRY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Surgery Partners Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGRY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGRY

Analyst Price Target is $43.75
▲ +49.83% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Surgery Partners in the last 3 months. The average price target is $43.75, with a high forecast of $72.00 and a low forecast of $35.00. The average price target represents a 49.83% upside from the last price of $29.20.

This chart shows the closing price for SGRY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Surgery Partners. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/10/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/23/2022Royal Bank of CanadaLower TargetOutperform$58.00 ➝ $48.00Low
11/23/2022JPMorgan Chase & Co.Lower Target$57.00 ➝ $45.00Low
11/22/2022Stifel NicolausLower Target$44.00 ➝ $36.00Low
11/22/2022SVB LeerinkLower TargetOutperform$55.00 ➝ $40.00Low
11/16/2022CowenLower Target$35.00Low
11/10/2022Royal Bank of CanadaLower TargetOutperform$62.00 ➝ $58.00Low
11/10/2022SVB LeerinkLower TargetOutperform$57.00 ➝ $55.00Low
11/9/2022CitigroupLower TargetBuy$49.00 ➝ $38.00Low
8/9/2022CowenLower Target$39.00Low
8/3/2022Royal Bank of CanadaLower TargetOutperform$65.00 ➝ $62.00N/A
6/15/2022Bank of AmericaDowngradeBuy ➝ Neutral$55.00 ➝ $36.00High
5/4/2022BenchmarkBoost Target$65.00 ➝ $72.00High
5/4/2022CitigroupBoost Target$61.00 ➝ $64.00High
3/2/2022JPMorgan Chase & Co.Boost TargetNeutral$50.00 ➝ $55.00Low
3/2/2022SVB LeerinkBoost TargetOutperform$63.00 ➝ $65.00High
3/1/2022Royal Bank of CanadaLower TargetOutperform$70.00 ➝ $65.00Medium
1/26/2022SVB LeerinkBoost TargetOutperform$61.00 ➝ $63.00Low
12/3/2021SVB LeerinkBoost TargetOutperform$52.00 ➝ $61.00Medium
11/30/2021BarclaysInitiated CoverageOverweight$73.00Medium
11/29/2021Stifel NicolausUpgradeHold ➝ Buy$51.00High
11/3/2021SVB LeerinkBoost TargetOutperform$50.00 ➝ $52.00High
11/1/2021JPMorgan Chase & Co.Initiated CoverageNeutral$50.00Medium
10/18/2021SVB LeerinkInitiated CoverageOutperform$50.00Medium
9/9/2021CowenInitiated CoverageMarket Perform$50.00High
6/22/2021Stifel NicolausInitiated CoverageHoldMedium
5/6/2021Royal Bank of CanadaBoost TargetOutperform$54.00 ➝ $61.00High
3/11/2021Royal Bank of CanadaBoost TargetOutperform$36.00 ➝ $54.00Low
12/10/2020Smith Barney CitigroupBoost TargetBuy$28.00 ➝ $35.00Low
9/17/2020Bank of AmericaBoost TargetBuy$21.50 ➝ $25.00Low
9/17/2020BenchmarkBoost TargetBuy$23.00 ➝ $28.00Low
8/7/2020CitigroupBoost TargetBuy$15.00 ➝ $23.00Low
8/6/2020Royal Bank of CanadaReiterated RatingBuy$23.00Low
7/27/2020UBS GroupLower TargetNeutral$19.00 ➝ $17.50Low
7/16/2020BenchmarkBoost TargetBuy$14.00 ➝ $18.00High
5/13/2020Royal Bank of CanadaReiterated RatingBuy$14.00Low
5/13/2020CitigroupBoost TargetBuy$10.00 ➝ $15.00High
4/27/2020BenchmarkUpgradeHold ➝ Buy$14.00High
4/20/2020Royal Bank of CanadaReiterated RatingBuy$14.00High
3/24/2020Royal Bank of CanadaLower TargetOutperform$19.00 ➝ $14.00High
3/6/2020Royal Bank of CanadaLower TargetPositive ➝ Outperform$22.00 ➝ $19.00High
3/3/2020BenchmarkDowngradeBuy ➝ HoldHigh
2/20/2020UBS GroupBoost TargetNeutral$12.00 ➝ $19.00High
1/14/2020BenchmarkBoost TargetBuy$13.00 ➝ $19.00High
12/10/2019CitigroupBoost TargetBuy$13.00 ➝ $20.00Low
5/8/2019Stifel NicolausSet TargetHold$12.00High
11/15/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$15.00High
9/18/2018Bank of AmericaUpgradeNeutral ➝ BuyHigh
8/13/2018SVB LeerinkBoost TargetOutperform$20.00 ➝ $25.00Low
8/10/2018Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$18.00 ➝ $20.00Low
8/7/2018SVB LeerinkInitiated CoverageOutperform$20.00Medium
6/28/2018Stifel NicolausUpgradeSell ➝ Hold$15.00Low
4/10/2018Stifel NicolausLower TargetSell ➝ Sell$17.00 ➝ $15.00High
3/1/2018Jefferies Financial GroupSet TargetBuy$18.00High
1/30/2018BenchmarkSet TargetBuy ➝ Buy$15.00 ➝ $19.00Low
(Data available from 12/5/2017 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
7/8/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/7/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/6/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/6/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/5/2022
  • 6 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
12/5/2022

Current Sentiment

  • 6 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Surgery Partners logo
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Read More

Today's Range

Now: $29.20
Low: $27.66
High: $29.29

50 Day Range

MA: $26.22
Low: $22.30
High: $29.78

52 Week Range

Now: $29.20
Low: $20.46
High: $63.87

Volume

589,200 shs

Average Volume

581,709 shs

Market Capitalization

$2.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Surgery Partners?

The following sell-side analysts have issued reports on Surgery Partners in the last year: Bank of America Co., Benchmark Co., Citigroup Inc., Cowen Inc., JPMorgan Chase & Co., Royal Bank of Canada, Stifel Nicolaus, StockNews.com, and SVB Leerink LLC.
View the latest analyst ratings for SGRY.

What is the current price target for Surgery Partners?

8 Wall Street analysts have set twelve-month price targets for Surgery Partners in the last year. Their average twelve-month price target is $43.75, suggesting a possible upside of 49.8%. Benchmark Co. has the highest price target set, predicting SGRY will reach $72.00 in the next twelve months. Cowen Inc. has the lowest price target set, forecasting a price of $35.00 for Surgery Partners in the next year.
View the latest price targets for SGRY.

What is the current consensus analyst rating for Surgery Partners?

Surgery Partners currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SGRY will outperform the market and that investors should add to their positions of Surgery Partners.
View the latest ratings for SGRY.

What other companies compete with Surgery Partners?

How do I contact Surgery Partners' investor relations team?

Surgery Partners' physical mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The company's listed phone number is (615) 234-5900 and its investor relations email address is [email protected] The official website for Surgery Partners is www.surgerypartners.com. Learn More about contacing Surgery Partners investor relations.